Cirrhosis
On this page
Direct answer
Cirrhosis is the end stage of chronic liver injury: diffuse fibrosis with regenerative nodules that destroy normal hepatic architecture and bridge portal tracts to central veins with portosystemic shunting. Micronodular cirrhosis, with nodules under 3 mm, typifies alcohol and metabolic disease; macronodular cirrhosis with larger, uneven nodules follows chronic viral hepatitis; mixed patterns are common as disease evolves. Whatever the cause — viral, alcohol, fatty liver, biliary, autoimmune or metabolic — the consequences are the same: portal hypertension with varices and ascites, hepatocellular failure with coagulopathy and encephalopathy, and heightened hepatocellular carcinoma risk.
What you must remember
- Definition: irreversible (in structural terms) diffuse process of fibrosis plus nodular regeneration, hepatocyte collapse and vascular rearrangement, stellate cells transdifferentiated into collagen-secreting myofibroblasts.
- Micronodular (Laennec): uniform nodules below 3 mm — alcoholic liver disease and metabolic storage diseases such as haemochromatosis.
- Macronodular (post-necrotic): nodules above 3 mm of varied size — chronic hepatitis B and C, autoimmune hepatitis and Wilson disease; mixed cirrhosis when longstanding.
- Indian context: chronic hepatitis B and C and alcohol remain major causes, while metabolic-associated fatty liver disease is rising steeply; biliary cirrhosis from primary biliary cholangitis or primary sclerosing cholangitis leaves a green, cholestatic liver.
- Complications of portal hypertension: oesophageal and gastric variceal bleeding, congestive splenomegaly with hypersplenism, ascites with spontaneous bacterial peritonitis risk, and portosystemic encephalopathy.
- Complications of hepatocellular failure: hypoalbuminaemia with oedema, coagulopathy from synthetic failure, jaundice, hyperoestrogenaemic features — spider naevi, palmar erythema, gynaecomastia — and hepatorenal and hepatopulmonary syndromes.
- Assessment and surveillance: Child-Turcotte-Pugh scoring (bilirubin, albumin, prothrombin, ascites, encephalopathy) and MELD for transplant priority; six-monthly ultrasound with alpha-fetoprotein for hepatocellular carcinoma surveillance per current guidance.
Common confusion
Micronodular versus macronodular turns on nodule size and cause — small and uniform with alcohol, large and irregular with viral hepatitis — but any cirrhosis can evolve into a mixed pattern, so answer from the dominant aetiology. Cirrhosis is a response to injury, not a disease itself: every stem hides a cause that must be named, from HBsAg positivity to antimitochondrial antibody. Finally, remember that fibrosis can stabilise with aetiology-directed treatment, but the established nodular architecture does not reverse.
Exam-focused takeaway
Questions give a stigmata photograph — spider naevi, caput medusae, ascites, Dupuytren contracture in alcoholics — or a gross liver photograph with micronodules, then ask the aetiology. One-liners test the Child-Pugh components, the stellate cell as the fibrogenic engine, and surveillance intervals for hepatocellular carcinoma. Tie each cause to its nodule size, and each complication to portal hypertension or failure.
Frequently asked questions
How is cirrhosis defined pathologically?
Diffuse fibrosis with regenerative nodules replacing normal lobular architecture, producing vascular shunts between portal and hepatic veins.
What separates micronodular from macronodular cirrhosis?
Nodules under 3 mm, uniform, typical of alcohol and metabolic disease versus nodules over 3 mm, irregular, typical of chronic viral hepatitis and autoimmune disease.
Which cell produces cirrhotic fibrosis?
Activated stellate cells (Ito cells) transdifferentiated into myofibroblasts depositing type I collagen in the space of Disse.
What are the two mechanistic groups of cirrhotic complications?
Portal-hypertensive complications (variceal bleeding, splenomegaly, ascites) and hepatocellular failure complications (coagulopathy, encephalopathy, hypoalbuminaemia).
How is hepatocellular carcinoma surveillance performed in cirrhosis?
Six-monthly abdominal ultrasound with or without alpha-fetoprotein, per current guidance, since cirrhosis is the strongest risk factor.